CVS Caremark Announces Agreement with FTC To Further Advance Industry-Leading Approaches to Transparency and Affordability

Rhea-AI Summary

CVS (NYSE: CVS), through CVS Caremark, announced a global settlement with the Federal Trade Commission that resolves all outstanding FTC litigation and investigations involving its pharmacy benefit management and affiliated pharmacy businesses, including rebate, pharmacy network contracting, and vertical integration issues.

According to CVS Caremark, the agreement removes ongoing legal overhang and formalizes a series of changes aimed at affordability and transparency, such as aligning member cost sharing with net drug costs, moving away from rebate guarantees and spread pricing, and expanding detailed reporting on drug prices, rebates, and member payments.

CVS Caremark reported negotiating nearly $80 billion in client and member prescription savings last year, delivering nearly $900 million in point-of-sale rebates to 25 million Americans, and expects clients to drive about $450 million in annual savings over each of the next 10 years through expanded point-of-sale rebate adoption and related innovations.

Positive

• Global FTC settlement resolves all outstanding litigation and investigations
• CVS Caremark negotiated nearly $80 billion in prescription drug savings last year
• Point-of-sale rebates delivered nearly $900 million to 25 million Americans last year
• Expected client savings of about $450 million per year for next 10 years
• Insulin affordability program capping member costs at $25 per month
• Transition to acquisition-based reimbursement may improve alignment with independent pharmacy costs

Negative

• Settlement requires multiple structural changes to pricing and transparency practices under FTC-established timelines

News Explained

The settlement makes CVS Caremark’s listed commercial-client affordability and transparency measures committed implementation items, but dates and financial effects remain unspecified.

The July 14, 2026 release says the FTC settlement is now the framework under which CVS Caremark will implement specified affordability, pricing, and reporting measures in its standard commercial-client offering.

The listed changes include tying certain member cost sharing more closely to post-rebate drug costs, moving away from rebate guarantees and spread pricing, expanding reporting on rebates and compensation, and shifting independent-pharmacy reimbursement toward acquisition costs.

Some provisions remain conditional: TrumpRx purchases will count toward deductibles and out-of-pocket maximums only where permitted by law and subject to settlement conditions, while a new insulin offering is described at $25 per month.

The concrete follow-up is implementation against timelines established with the FTC; the release does not provide dates for those timelines or quantify the financial effect of the operating changes.

Argus Jul 14 session

+0.26% close to close Open Argus

Details

News Market Reaction – CVS

On Jul 14, the day this news came out, CVS closed 0.26% above the previous close.

Data tracked by StockTitan Argus for the Jul 14 session.

Key Figures

Client drug savings: nearly $80 billion Point-of-sale savings: nearly $900 million Members benefiting: 25 million Americans +5 more

Client drug savings

nearly $80 billion

Savings negotiated for clients and members on prescription drugs last year

Point-of-sale savings

nearly $900 million

Savings delivered via point-of-sale rebates last year

Members benefiting

25 million Americans

Members receiving point-of-sale rebate savings last year

Expected annual savings

$450 million per year

Estimated savings for clients each year over the next 10 years

Savings duration

10 years

Time period for expected $450 million annual savings

Insulin cost cap

$25 per month

New offering to cap members’ insulin costs under affordability programs

Network pharmacies

more than 60,000

Pharmacies nationwide offering $25/month insulin through ReducedRx

Insulin pricing

$25/month insulin

ReducedRx program offering insulin at $25/month at network pharmacies

Historical Context

5 past events · Latest: Jul 10

5 events

1. Jul 10

   Dividend declaration

   24h Move

   +1.3%

   Board approved a quarterly cash dividend of $0.665 per share.

2. Jul 06

   Earnings call scheduling

   24h Move

   -2.5%

   Announced date and time for second quarter 2026 earnings call.

3. Jun 25

   Community investment

   24h Move

   +2.7%

   Committed $1 million in Hometown Fund grants to 20 Hartford nonprofits.

4. Jun 25

   Community investment

   24h Move

   +2.7%

   Invested $1 million via Hometown Fund in 20 Rhode Island nonprofits.

5. Jun 22

   GLP‑1 program expansion

   24h Move

   +3.6%

   Expanded GLP‑1 support and lower-cost access, including defined monthly copay options.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

point-of-sale rebates, rebate guarantees, spread pricing, acquisition-based reimbursement, +2 more

6 terms

point-of-sale rebates financial

"As an early advocate of offering point-of-sale rebates to our clients"

Point-of-sale rebates are discounts or payments applied at the time a purchase is completed, where the buyer pays less up front because a manufacturer, insurer, or retailer covers part of the cost immediately. Think of it like handing over a coupon that the cashier honors on the spot rather than sending in for later. For investors, these rebates affect reported sales, margins, and cash flow because they reduce the price received and can change how much revenue is recognized and how demand responds to final consumer prices.

rebate guarantees financial

"Simplifying pricing structures by moving away from rebate guarantees and spread pricing"

A contractual promise by a seller or manufacturer to return a portion of revenue to a buyer, payer, or intermediary if certain conditions are met, such as meeting volume targets, price thresholds, or formulary placement requirements. Think of it like a store promising a partial refund later if a customer or partner meets agreed criteria; for investors this creates future payment obligations and can change reported revenue, cash flow timing, and the company’s liability profile.

spread pricing financial

"Simplifying pricing structures by moving away from rebate guarantees and spread pricing"

Spread pricing is the difference between the price at which a market participant can buy an asset and the price at which they can sell it — the “buy” versus “sell” gap set by dealers or exchanges. It matters to investors because that gap is a hidden cost and a sign of liquidity: wider spreads raise trading costs and signal harder-to-trade or riskier markets, while tighter spreads lower costs and indicate smoother trading.

acquisition-based reimbursement financial

"Transitioning to acquisition-based reimbursement for independent retail pharmacies"

A payment method in healthcare and medical supply markets where a payer reimburses a provider or supplier based on the actual purchase price (acquisition cost) of a drug, device, or supply rather than a fixed list price or wholesale rate. It matters to investors because it directly affects a seller’s revenue and margins and changes pricing incentives—like being paid back for groceries using your receipt instead of a store’s advertised price, which alters profit depending on the purchase price.

biosimilars medical

"accelerating the adoption of lower cost biosimilars through formulary strategies"

Biosimilars are medicines made to be highly similar to an already approved biological drug produced from living cells, with no meaningful differences in safety or effectiveness. They matter to investors because they introduce lower‑cost competition to expensive biologic treatments—similar to how generic drugs compete with brand drugs—but involve more complex manufacturing, regulatory review and patent risk, which can affect market share, pricing and profit margins across the sector.

deductibles financial

"Counting TrumpRx purchases toward member deductibles and out-of-pocket maximums"

Deductibles are the amount of money you pay out of pocket for expenses before your insurance or coverage begins to pay. For example, if you have a deductible of $500, you cover the first $500 of costs yourself, and then the insurance helps with the remaining expenses. Understanding deductibles helps investors gauge the potential costs and risks associated with insurance plans or financial protections.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WOONSOCKET, R.I., July 14, 2026 /PRNewswire/ -- CVS Caremark today announced a global settlement with the Federal Trade Commission (FTC) which further advances the company's leadership in delivering greater affordability for prescription drugs. The settlement resolves all outstanding FTC litigation and investigations related to CVS Health^® (NYSE: CVS) — including its pharmacy benefits management and affiliated pharmacy businesses — involving rebate, pharmacy network contracting, and vertical integration issues.

The agreement eliminates the need for ongoing litigation and investigations and allows CVS Caremark to remain focused on delivering more value for American consumers and employers, lowering prescription drug costs, increasing transparency, and helping customers deliver affordable health care to the people they serve.

"CVS Caremark has led the industry in evolving the pharmacy benefit management model and has delivered value to our customers and clients," said Ed DeVaney, Executive Vice President CVS Health and President, CVS Caremark. "Today's agreement advances and reinforces the changes we have already put in place and ensures affordability for families and patients across the country. CVS Caremark remains committed to lowering costs and bringing greater transparency to prescription drug pricing."

The changes CVS Caremark has made, and continues to make, are lowering the cost of health care for millions of people:

• Last year alone, CVS Caremark negotiated with pharmaceutical companies to save our clients and their members nearly $80 billion on their prescription drugs.
• As an early advocate of offering point-of-sale rebates to our clients, CVS Caremark delivered nearly $900 million in savings to 25 million Americans just last year.
• Through greater client adoption of point-of-sale rebates, and continued innovation, we expect to help our clients drive estimated savings of $450 million per year for each of the next 10 years.

As outlined in the agreement CVS Caremark will implement a series of actions into its standard offering to commercial clients, including:

• Aligning certain member cost sharing more closely with the net cost of medications after rebates to help push more savings to members at the point-of-sale
• Simplifying pricing structures by moving away from rebate guarantees and spread pricing
• Expanding transparency through enhanced reporting on drug pricing, rebates, and member payments, along with disclosure of broker and consultant compensation
• Expanding affordability programs for medicines, including a new offering that will cap members' insulin costs at $25 per month
• Promoting point-of-sale rebate passthrough as a standard option to encourage plan sponsors to share drug cost savings more directly with members at the pharmacy counter
• Delinking manufacturer compensation from list prices
• Transitioning to acquisition-based reimbursement for independent retail pharmacies to ensure reimbursements are more closely aligned with their actual costs
• Counting TrumpRx purchases toward member deductibles and out-of-pocket maximums where allowed by law, subject to certain conditions in the settlement

CVS Caremark continues to introduce innovations that simplify the pharmacy experience and help lower prescription drug costs. These efforts include expanding automated prior authorization technology, accelerating the adoption of lower cost biosimilars through formulary strategies, and offering benefit designs that provide greater transparency and predictability in prescription pricing.

Many of the measures in the agreement align with CVS Caremark's existing affordability and transparency initiatives, including point-of-sale rebate options, flat-dollar copays, copay caps, $0 preventive drug lists, and the TrueCost™ pricing model each designed to reduce out-of-pocket costs and provide greater clarity at the drug level. These efforts also include ReducedRx^®, which offers $25/month insulin at more than 60,000 network pharmacies nationwide. In addition, Aetna has been providing fully insured commercial clients with point-of-sale rebates since 2019.

CVS Caremark will begin implementing the provisions of the agreement in accordance with timelines established with the FTC and will continue working with regulators, employers, and industry partners to strengthen transparency and affordability across the pharmacy benefit system.

About CVS Health
CVS Health is a leading health solutions company simplifying health care one person, one family and one community at a time. As of March 31, 2026, the Company had approximately 9,000 retail pharmacy locations, more than 1,000 walk-in and primary care medical clinics and a leading pharmacy benefits manager with approximately 88 million plan members. The Company also serves an estimated more than 37 million people through a broad range of health insurance products and related services. The Company's integrated model uses personalized, technology driven services to connect people to simply better health, increasing access to quality care, delivering better outcomes, and lowering overall costs.

Media contact
Ethan Slavin
860-273-6095
Ethan.Slavin@CVSHealth.com

Investor contact
Larry McGrath
800-201-0938
InvestorInfo@CVSHealth.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/cvs-caremark-announces-agreement-with-ftc-to-further-advance-industry-leading-approaches-to-transparency-and-affordability-302825537.html

SOURCE CVS Health

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What is the CVS (NYSE: CVS) global settlement with the FTC announced on July 14, 2026?

The settlement is an agreement between CVS Caremark and the FTC resolving all outstanding litigation and investigations. According to CVS Caremark, it covers rebate, pharmacy network contracting, and vertical integration issues tied to its pharmacy benefits and affiliated pharmacy businesses.

How will the CVS Caremark FTC settlement affect prescription drug affordability for CVS (CVS) members?

The agreement is designed to push more savings directly to members at the pharmacy counter. According to CVS Caremark, it aligns cost sharing with net drug costs, expands point-of-sale rebates, and introduces affordability programs such as a $25-per-month insulin offering.

What specific changes is CVS Caremark making under the FTC agreement for CVS (CVS) commercial clients?

CVS Caremark will standardize several features in its commercial offering, including simplified pricing without rebate guarantees, expanded transparency reporting, and acquisition-based reimbursement for independent pharmacies. According to CVS Caremark, it will also promote point-of-sale rebate passthrough as a standard option.

How much did CVS Caremark report saving clients and members on prescriptions before the 2026 FTC settlement?

CVS Caremark reported negotiating nearly $80 billion in prescription savings for clients and members last year. According to CVS Caremark, it also delivered nearly $900 million in point-of-sale rebate savings to about 25 million Americans over the same period.

What long-term savings does CVS Caremark expect from increased point-of-sale rebates for CVS (CVS) clients?

CVS Caremark expects its clients to achieve about $450 million in savings per year over the next 10 years. According to CVS Caremark, this estimate is tied to greater adoption of point-of-sale rebates and continued pricing innovation.

How does the CVS Caremark $25 insulin program relate to the FTC settlement for CVS (CVS)?

The company highlights an affordability program that will cap insulin costs at $25 per month for members. According to CVS Caremark, this new offering is part of broader measures to expand affordability initiatives aligned with the agreement.

When will CVS Caremark begin implementing the FTC settlement provisions affecting CVS (CVS) stakeholders?

CVS Caremark plans to roll out the settlement provisions according to timelines agreed with the FTC. According to CVS Caremark, it will continue collaborating with regulators, employers, and industry partners to strengthen transparency and affordability in the pharmacy benefit system.